



17th Executive Board
3 – 5 December 2012
WHO Headquarters, Salle D
Geneva, Switzerland

Resolution n°7

2012 Paediatric ARV Call- DNDI Market entry of an improved solid protease inhibitor-based first-line antiretroviral combination therapy for infants and young children with HIV/AIDS

Taking into account the outcome of the PRC review of 23-26 October, 2012, the Board of UNITAID, subject to the availability of funds, authorizes the Executive Director to commit up to USD**17,336,000** for the project *Market entry of an improved solid protease inhibitor-based first-line antiretroviral combination therapy for infants and young children with HIV/AIDS*.

Lead organization (s): DNDi

Lead recipient: DNDi

Conditions for UNITAID funding support:

Funding is conditional upon:

1. Clarifications provided to the Secretariat to the issues set out in the annex
2. Signature of a legal agreement between DNDi and UNITAID

A handwritten signature in blue ink, appearing to read "Ph. Douste-Blazy".

Philippe Douste-Blazy
Chair of the UNITAID Executive Board